| Literature DB >> 17462080 |
Markolf Hanefeld1, Carsta Koehler, Silvina Gallo, Inge Benke, Petra Ott.
Abstract
BACKGROUND: One of the major controversies surrounding the metabolic syndrome (MetS) in type 2 diabetes is whether its single components act synergistically as risk factors for atherosclerotic vascular disease (AVD). We aimed to answer this by evaluating the relationship, and its various combinations to AVD in comparison to single traits in a population-based study with type 2 diabetes in Germany. METHODS ANDEntities:
Mesh:
Year: 2007 PMID: 17462080 PMCID: PMC1871572 DOI: 10.1186/1475-2840-6-13
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
| Number | 4020 | 2140 | 1880 |
| Age (years) a | 61.8 (8.1) | 61.2 (8.1) | 62.2 (8.0) |
| Diabetes duration (years) | 8.4 (6.8) | 8.2 (6.9) | 8.6 (6.7) |
| Current smoking (%) c | 15.0 | 18.9 | 10.5 |
| BMI (kg/m2) a | 30.7 (5.2) | 30.0 (4.5) | 31.6 (5.8) |
| Blood pressure (mmHg) systolic | 139 (17) | 139 (17) | 140 (18) |
| - diastolic | 82 (9) | 82 (9) | 82 (9) |
| Blood glucose (mmol/l) fasting | 7.6 (2.5) | 7.6 (2.5) | 7.5 (2.4) |
| - postprandialb | 9.2 (2.8) | 9.3 (2.8) | 9.0 (2.7) |
| HbA1c (%) | 7.0 (1.2) | 7.0 (1.3) | 7.0 (1.2) |
| Total cholesterol (mmol/l) a | 5.5 (1.2) | 5.4 (1.2) | 5.7 (1.2) |
| LDL-cholesterol (mmol/l) a | 3.2 (1.0) | 3.1 (1.0) | 3.4 (1.0) |
| HDL-cholesterol (mmol/l) a | 1.3 (0.4) | 1.2 (0.3) | 1.4 (0.4) |
| Triglycerides (mmol/l) b | 2.2 (1.7) | 2.3 (1.8) | 2.2 (1.7) |
| Creatinine (μmol/l) a | 82.9 (19.5) | 89.2 (18.9) | 75.7 (17.6) |
| Hypertension (%) | 91.3 | 91.3 | 91.4 |
| Low HDL-cholesterol (%) | 9.3 | 10.0 | 8.4 |
| Hypertriglyceridaemia (%) | 55.4 | 56.5 | 54.1 |
| Obesity (%) a | 49.8 | 44.4 | 55.9 |
| Only diabetes (%) | 2.4 | 2.6 | 2.2 |
| Antihypertensive therapy (%) | 72.9 | 71.2 | 74.8 |
| Medical treatment of diabetes (%) | |||
| - oral drugs | 42.3 | 44.1 | 40.4 |
| - insulin treatment | 44.8 | 41.0 | 44.9 |
| Therapy with statins (%) a | 27.9 | 29.3 | 26.2 |
| Therapy with fibrates (%) | 4.2 | 4.6 | 3.8 |
Baseline characteristics of the DIG population divided by sex. Data are mean (SD) and %. Gender differences a p < 0.05; b p < 0.01; c p < 0.001.
| DM+HBP+LHDL (%) | 9.7 | 10.6 | 8.6 |
| DM+HBP+HTG (%) | 55.9 | 57.1 | 54.6 |
| DM+HBP+Obes (%)a | 50.7 | 45.3 | 55.6 |
| DM+LHDL+HTG (%) | 8.4 | 8.7 | 7.9 |
| DM+LHDL+Obes (%) | 5.6 | 5.6 | 5.6 |
| DM+HTG+Obes (%)a | 33.7 | 31.1 | 36.6 |
| DM+HBP+LHDL+HTG (%) | 7.8 | 8.3 | 7.2 |
| DM+HBP+LHDL+Obes (%) | 5.3 | 5.5 | 5.2 |
| DM+HBP+HTG+Obes (%)a | 31.9 | 29.5 | 34.6 |
| DM+LHDL+HTG+Obes (%) | 4.7 | 4.8 | 4.6 |
| DM+HBP+LHDL+HTG+Obes (%) | 4.4 | 4.6 | 4.2 |
| DM + one trait (%) | 20.5 | 21.5 | 19.3 |
| DM + two traits (%) | 35.3 | 36.4 | 34.1 |
| DM + three traits (%)a | 27.2 | 25.1 | 29.5 |
| Overall MetS (%) | 74.4 | 73.2 | 75.8 |
Prevalence of the different phenotypes of MetS in the DIG population by sex.
Sex differences a p < 0.001.
| DM alone | 0.24 (0.09–0.67) | 0.23 (0.07–0.75) | 0.23 (0.03–1.66) |
| 1.29 (0.97–1.72) | 1.05 (0.73–1.52) | ||
| DM+HTG | 1.04 (0.87–1.26) | 0.94 (0.74–1.18) | 1.23 (0.89–1.70) |
| DM+Obes | 0.95 (0.79–1.13) | 0.96 (0.77–1.20) | 1.23 (0.89–1.71) |
| 1.14 (0.82–1.58) | 0.85 (0.55–1.31) | ||
| DM+LHDL+Obes | 0.90 (0.59–1.37) | 0.54 (0.29–1.01) | 1.76 (0.97–3.19) |
| DM+HTG+Obes | 0.96 (0.79–1.17) | 0.91 (0.71–1.17) | 1.20 (0.86–1.68) |
| 1.21 (0.87–1.69) | 0.90 (0.58–1.39) | ||
| 0.95 (0.62–1.46) | 0.56 (0.30–1.04) | ||
| DM+HBP+HTG+Obes | 1.01 (0.82–1.23) | 0.93 (0.72–1.21) | 1.29 (0.92–1.79) |
| DM+LHDL+HTG+Obes | 0.86 (0.54–1.38) | 0.47 (0.23–0.95) | 1.85 (0.97–3.52) |
| 0.92 (0.57–1.47) | 0.49 (0.24–1.00) | ||
Odds ratios (95% CI) for AVD of different phenotypes of MetS in the DIG population by sex
Figure 1OR (95% CI) for AVD in the DIG population divided by sex. Data are presented for overall MetS, single traits and their combinations of the MetS. Only those combinations with associated AVD events are displayed. The scale of OR was log-transformed.